Evidence map›Paper›PMID 42575949›Full record

ArticleEuropean journal of human genetics : EJHG2026

An episignature informed systematic analysis to ascertain the clinical significance and consequences of CHD8 missense variants.

Molly Godfrey, Michael A Levy, Christopher Campbell, Leigh Demain, Sarah Jenkinson, Sarah Hilton, Berta Almoguera, Meena Balasubramanian, Emilia K Bijlsma, Fiona Blanco-Kelly and 31 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Molly GodfreyManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK. molly.godfrey@mft.nhs.uk.ORCID http://orcid.org/0000-0002-1636-3434
Michael A LevyVerspeeten Clinical Genome Centre, London Health Sciences Centre, and Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada.
Christopher CampbellManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
Leigh DemainManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
Sarah JenkinsonManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
Sarah HiltonManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
Berta AlmogueraCentro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0002-5599-2954
Meena BalasubramanianSheffield Clinical Genomics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Emilia K BijlsmaDepartment of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
Fiona Blanco-KellyCentro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Emma M M Burkitt WrightManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
Gerarda CappuccioDepartment of Translational Medicine, Section of Pediatrics, Federico II University, Naples, Italy.
Kate E ChandlerManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
Koen DevriendtCentre for Human Genetics, University Hospital, University of Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3651-2548
Aranzazu Diaz de BustamanteUnidad de Genetica, Hospital Universitario de Mostoles, Mostoles, Spain.
Maria K HaanpääDepartment of Clinical Genetics, Turku University Hospital, Turku, Finland.
Carolin HörnigDepartment of Neuropediatrics, Jena University Hospital, Jena, Germany.
Elizabeth A JonesManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
Sinem KocagilDepartment of Medical Genetics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Turkey.ORCID http://orcid.org/0000-0003-2595-3919
Hannele KoillinenDepartment of Clinical Genetics, Turku University Hospital, Turku, Finland.
Dhanya Lakshmi NarayananDepartment of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.ORCID http://orcid.org/0000-0002-1627-3252
Emanuela LeonardiDepartment of Biomedical Sciences, University of Padova, Padova, Italy.ORCID http://orcid.org/0000-0001-8486-8461
Rajesh MadhuDepartment of Neurosciences, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Purvi MajethiaDepartment of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.
Alessandra MurgiaDepartment of Woman and Child Health, University of Padova, Padova, Italy.ORCID http://orcid.org/0000-0001-6788-0653
Elisabeth RosserDepartment of Clinical Genetics, Great Ormond Street Hospital for Children, London, UK.
Markus SchuelkeNeuroCure Cluster of Excellence, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.ORCID http://orcid.org/0000-0003-2824-3891
Anju ShuklaDepartment of Medical Genetics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.ORCID http://orcid.org/0000-0003-2471-4094
Emma Soengas-GondaCentro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0002-4640-1526
Sarah StewartManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
Yves SznajerCenter for Human Genetics Cliniques Universitaires Saint-Luc UCLouvain, Brussels, Belgium.ORCID http://orcid.org/0000-0001-8161-4490
Saoud Tahsin SwafiriCentro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0003-3684-9076
Maria Margarida VenancioDepartment of Genetics, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Renzo GuerriniPediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Meyer Children's Hospital, University of Florence, Florence, Italy.
Martino MontomoliPediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Meyer Children's Hospital, University of Florence, Florence, Italy.
Annalisa VetroPediatric Neurology, Neurogenetics and Neurobiology Unit and Laboratories, Meyer Children's Hospital, University of Florence, Florence, Italy.
Thomas WrightManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
David GokhaleManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.
Bekim SadikovicVerspeeten Clinical Genome Centre, London Health Sciences Centre, and Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada.ORCID http://orcid.org/0000-0001-6363-0016
Sofia Douzgou Houge *Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK.ORCID http://orcid.org/0000-0001-8890-7544
Siddharth Banka *Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS foundation Trust, Health Innovation Manchester, Manchester, UK. Siddharth.Banka@manchester.ac.uk.ORCID http://orcid.org/0000-0002-8527-2210

Funding

DBT India Alliance (Wellcome Trust/DBT India Alliance) IA/CRC/20/1/600002Ministerio de Sanidad, Servicios Sociales e Igualdad (Ministry of Health, Social Services and Equality) IMP/00009Norges Forskningsråd (Research Council of Norway) 358387Ontario Genomics Institute (OGI) OGI-188RCUK | Medical Research Council (MRC) MR/Y008170/1RCUK | MRC | Medical Research Foundation MR/V037307/1
6 · The paper itself

Abstract

Pathogenic CHD8 variants cause autosomal dominant 'Intellectual developmental disorder with autism and macrocephaly' (IDDAM) and are amongst the most common monogenic causes of autism. The clinical significance of CHD8 missense variants (MVs) frequently remains uncertain. Systematically applying ACGS/ACMG guidelines to 36 CHD8 MVs in 39 affected patients, only two variants were classified likely pathogenic (LP), with the remaining 34 classified variants of uncertain significance (VUS). We subclassified the variants according to posterior probability of pathogenicity (PPP), with 14 being at least tepid VUS (PPP ≥ 50%). Comprehensive phenotypic analysis revealed no discernible clinical differences between individuals carrying at least tepid VUS and others, offering no additional insight for variant classification. EpiSign™ testing revealed a CHD8-IDDAM episignature, as previously detected in patients with truncating/null variants, in 11 cases, allowing reclassification of 8 VUS (all previously classified at least tepid) as LP. Molecular modelling indicated that disease-causing (LP/P) CHD8 MVs are concentrated in structured and/or functional protein domains. Compared to truncating/null variants, disease-causing MVs were less often associated with attention issues and macrocephaly, but clinical features were otherwise similar. Additionally, three disease-causing MVs were inherited from unaffected/mildly affected parents. Overall, we show that determining the clinical significance of CHD8 MVs is challenging, even with detailed clinical information, but that incorporating episignature analysis increases diagnostic yield. Further, our results indicate that CHD8 MVs are likely to act via a loss-of-or reduced function mechanism. These findings reveal the importance and complexity of interpreting CHD8 MVs and will improve the diagnosis and understanding of CHD8-related disorders.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.